Bifidobacteria for treating diabetes and related conditions
AssigneeInternational N&H Denmark Aps
InventorsRemy Burcelin, Didier Carcano, Sampo Lahtinen
Life of this patent
Estimating the term…
Abstract
This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.
Claims9
A method of treating a disease or condition in a mammal, wherein the disease or condition is selected from:
- diabetes;
- impaired glucose tolerance;
- reduced insulin sensitivity:
- reduced fed insulin secretion;
- elevated fasted insulin secretion;
- elevated body fat mass;
- and
- elevated mesenteric fat mass;
- and the method comprises:
- administering to a mammal in need of such treatment Bifidobacterium animalis subsp. lactis strain 420 such that an effect of the treatment of the disease or the condition is selected from:
- reducing plasma insulin;
- reducing body weight gain following a high fat diet;
- increasing insulin sensitivity following the high fat diet;
- or
- reducing liver and muscle tissue inflammation following the high fat diet.
Dependencies are inferred from the claim text.